| abstract |
The present invention provides novel human anti-huntingtin (HTT) antibodies and biotechnological derivatives thereof, preferably capable of binding mutated and/or aggregated HTT species and/or fragments thereof, and methods related to them. The human-derived anti-HTT antibodies and biotech derivatives can be used in HTT-directed immunotherapy for Huntington's disease and in pharmaceuticals and diagnostic compositions for the diagnosis of Huntington's disease. |